News and Trends 8 Sep 2022 Lutris Pharma radiation trial brings positive results for breast cancer patients Top line results from a clinical trial treating breast cancer patients with radiation dermatitis (RD) have been positive. Lutris Pharma, based in Israel, is a biopharma company focused on improving cancer therapies. It announced its results from the open label part 1 and double blinded part 2 of it phase 1/2 trial yesterday (September 7). […] September 8, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Report looks at the future of clinical trials Medidata, a Dassault Systèmes company, has published a report, ‘European Industry Research Report: The Future of Clinical Trials’. The report draws on new independent research that includes insights from 400 clinical trial executives across the U.K., France, Germany and Switzerland. They were surveyed to gain a deeper understanding of how clinical trials have changed over […] September 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Adocia takes steps with implants for treatment of type 1 diabetes French biopharma company Adocia has established a first proof of concept for its AdoShell Islets implant by achieving glycemic control without insulin injections in immunocompetent diabetic rats during a 132-day study. AdoShell Islets is an immuno-protective synthetic biomaterial containing islets of Langerhans. After implantation in diabetic animals, the islets encapsulated in AdoShell secrete insulin in […] September 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 OncoResponse and Regeneron to evaluate drug combo for patients with advanced cancer OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, has announced a clinical supply agreement with Regeneron for PD-1 inhibitor Libtayo (cemiplimab). The supply agreement with Regeneron will support the evaluation of Libtayo in combination with OR2805, a fully human monoclonal antibody identified from an elite cancer responder […] September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Alzinova announces new positive safety review for Alzheimer’s study Alzinova AB says a second external safety review has been carried out of its clinical phase 1b study. This resulted in a positive assessment to continue the study as planned. Behind the review is an independent expert group, Data and Safety Monitoring Board (DSMB), which continuously reviews the study. Based on the patients included in […] September 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Ionis presents positive study results at International Symposium on amyloidosis Ionis Pharmaceuticals, Inc. has presented positive results from a planned 35-week interim analysis of the phase 3 NEURO-TTRansform study of Ionis and AstraZeneca’s eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). In the study, eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for its co-primary and secondary efficacy endpoints compared to […] September 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 IRLAB’s partner Ipsen starts mesdopetam clinical studies IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, says its partner, Ipsen, has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan. These are standard clinical pharmacokinetic studies that will run in parallel to the phase IIb study with […] September 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 Innovent starts trial of mazdutide in Chinese adults with obesity Innovent Biologics, Inc. says the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical trial of mazdutide, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with obesity. This randomized, double-blinded, placebo-controlled study was designed to evaluate the efficacy and safety of mazdutide […] September 6, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2022 First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib The first patient has been dosed in a phase 2 trial looking at a drug to treat peripheral T cell lymphomas – a heterogenous group of generally aggressive neoplasms. Yingli Pharma made the announcement on Saturday (September 3) that patients were being dosed with linperlisib – a potent inhibitor of the delta isoform of PI3 […] September 5, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2022 Sanofi and Regeneron’s Dupixent shows sustained improvement in lung function in children A maintenance therapy from Sanofi and Regeneron, added to other asthma medications, has shown sustained improvement in lung function, low-rate of asthma attacks and a consistent safety profile for up to two years in children. Results from the longest global phase 3 open-label extension trial in the age group six to 11 years old with […] September 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2022 Astellas ‘encouraged’ by menopause symptom treatment results in China Astellas Pharma Inc. has announced topline results from its phase 3 MOONLIGHT 3 clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night […] September 5, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2022 Synairgen to collaborate on study of patients hospitalized due to respiratory viruses Synairgen plc is to collaborate on a University of Southampton study on acute respiratory viral infection and recovery in hospital patients. The UNIVERSAL (Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal) trial is an observational study being led by the Clinical Trials Unit of the University of Southampton in the U.K. to explore and […] September 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email